CNCure Co., Ltd.

CNCure Co., Ltd. is a South Korea–based biotechnology company headquartered in Hwasun-gun, Jeonnam, focusing on cancer theranostics that combine therapy and diagnostics for precision medicine. The company develops bacteria-based cancer immunotherapies and imaging/radiotheranostic technologies to improve treatment outcomes and enable proactive, personalized care. CNCure’s R&D is centered on microbial (bacteria)-based cancer immunotherapies, with its lead preclinical candidate CNC-101 designed to reprogram the tumor microenvironment and enhance anti-tumor immunity as a genetically attenuated Salmonella typhimurium platform strain. In parallel, CNC-105 is being developed as a drug delivery system encoding exogenous genes that are expressed in the tumor microenvironment under a tightly controlled expression system to maximize efficacy and safety and to minimize toxicity and side effects. The company also advances molecular imaging probes and radio-theranostic agents, including 18F-labeled tracers, to enable simultaneous diagnosis and therapy within a precision oncology framework. Within this portfolio, CNC-201 is positioned as a diagnostic radiopharmaceutical for detecting malignant melanoma, CNC-211 is designed to detect gram-negative bacterial or yeast infections, and CNC-301 is an RPT (radiopharmaceutical therapy) candidate targeting malignant melanoma. CNCure was founded in 2019, with its main site located at the Chonnam National University Biomedical Research Center in Hwasun, Jeollanam-do, South Korea. It operates as a privately held biotech company and has been recognized as a JLABS Korea portfolio company in 2024 and 2025, while also being supported as an innovation-driven startup through multiple national R&D and drug development programs.